StoneX Group’s Impact BioMedical IBO Stock Holding History

StoneX Group’s Portfolio IBO Stock Details IBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,794	Closed	-$6.99K	–	1053
2025 Q2	$6.99K	Buy	+10,794	New	+$6.05K	﹤0.01%	845

Other funds holding IBO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAC

Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

StoneX Group's IBO Position: Q3 2025 in Review

StoneX Group sold out of Impact BioMedical (IBO) in Q3 2025, closing a stake of 10,794 shares — an estimated $6.99K sold.

StoneX Group first reported a position in IBO in Q2 2025 and held it in 1 quarter. The position peaked at $6.99K in Q2 2025. 21 funds tracked by Wall St. Rank hold IBO as of Q3 2025.

StoneX Group reported no remaining Impact BioMedical position as of Q3 2025 after selling out during the quarter.
StoneX Group sold 10,794 Impact BioMedical shares in Q3 2025, an estimated $6.99K.
StoneX Group first reported a position in Impact BioMedical in Q2 2025 and held it in 1 quarter.
StoneX Group's Impact BioMedical position peaked at $6.99K in Q2 2025.
21 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2025.

Based on StoneX Group's 13F filing for Q3 2025, filed 14 Nov 2025.